| 产品名称： | MC/CAR |
|---|---|
| 商品货号： | TS211526 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | plasmacytoma; myeloma |
| Age： | 81 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： |
Can be used as a human fusion line.
|
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | normal male diploid |
| Derivation： | Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line. |
| Clinical Data： | male Caucasian 81 years |
| Antigen Expression： | HLA A1, A33/31, B7, B18, DRw1, DRw2; CD11a +; CD19 +; CD20 + CD28 -; CD38 + |
| Receptor Expression： | complement (C3b) |
| Genes Expressed： | immunoglobulin |
| Cellular Products： | immunoglobulin |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice inoculated subcutaneously with 107 cells
(Tumors developed within 21 days at 100% frequency (5/5).) |
| Comments： | The cells produce, but do not secrete, immunoglobulin.
No surface immunoglobulin. 8-azaguanine mutants may be cloned out or mutagenized for HAT sensitive cultures.
|
| Complete Growth Medium： | Iscoves modified Dulbeccos medium, 80%; fetal bovine serum, 20%
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 x 105 cells/mL and maintain between 5 x 105 and 1 x 106 cells/mL.
Medium Renewal: Two to three times weekly. |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,13 D16S539: 11,12 D5S818: 11,14 D7S820: 9,13 THO1: 6,9 TPOX: 8 vWA: 17,18 |
| Isoenzymes： | ADA, 1 AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 PGM1, 1 PGM3, 1 |
| Isotype： | IgG1 (cytoplasmic); kappa light chain |
| Name of Depositor： | Research Corporation |
| U.S. Patent Number： | |
| References： | Ritts RE Jr.. Human nonsecretory plasmacytoid cell line. US Patent 4,434,230 dated Feb 28 1984 Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375 Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762 Ritts RE J, et al. Establishment and characterization of a human non-secretory plasmacytoid cell line and its hybridization with human B cells. Int. J. Cancer 31: 133-141, 1983. PubMed: 6600719 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | MC/CAR |
|---|---|
| 商品货号： | TS211526 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | plasmacytoma; myeloma |
| Age： | 81 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： |
Can be used as a human fusion line.
|
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | normal male diploid |
| Derivation： | Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line. |
| Clinical Data： | male Caucasian 81 years |
| Antigen Expression： | HLA A1, A33/31, B7, B18, DRw1, DRw2; CD11a +; CD19 +; CD20 + CD28 -; CD38 + |
| Receptor Expression： | complement (C3b) |
| Genes Expressed： | immunoglobulin |
| Cellular Products： | immunoglobulin |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice inoculated subcutaneously with 107 cells
(Tumors developed within 21 days at 100% frequency (5/5).) |
| Comments： | The cells produce, but do not secrete, immunoglobulin.
No surface immunoglobulin. 8-azaguanine mutants may be cloned out or mutagenized for HAT sensitive cultures.
|
| Complete Growth Medium： | Iscoves modified Dulbeccos medium, 80%; fetal bovine serum, 20%
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 x 105 cells/mL and maintain between 5 x 105 and 1 x 106 cells/mL.
Medium Renewal: Two to three times weekly. |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,13 D16S539: 11,12 D5S818: 11,14 D7S820: 9,13 THO1: 6,9 TPOX: 8 vWA: 17,18 |
| Isoenzymes： | ADA, 1 AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 PGM1, 1 PGM3, 1 |
| Isotype： | IgG1 (cytoplasmic); kappa light chain |
| Name of Depositor： | Research Corporation |
| U.S. Patent Number： | |
| References： | Ritts RE Jr.. Human nonsecretory plasmacytoid cell line. US Patent 4,434,230 dated Feb 28 1984 Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375 Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762 Ritts RE J, et al. Establishment and characterization of a human non-secretory plasmacytoid cell line and its hybridization with human B cells. Int. J. Cancer 31: 133-141, 1983. PubMed: 6600719 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
